Other studies demonstrated that the co-inhibition of CSF1-R and SHP2 using nanoparticles loaded with inhibitors for tumor TAM activation and enhancement of phagocytosis is an effective strategy for macrophage-based antitumor immunotherapy (Ramesh et al., 2019). Here, CSF1R is linked to neoplasm.